about
MAPK scaffold IQGAP1 binds the EGF receptor and modulates its activationNrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancerInduction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasoundLRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysisThe ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferationErbB receptors: from oncogenes to targeted cancer therapiesBAD: a good therapeutic target?Update on HER-2 as a target for cancer therapy: alternative strategies for targeting the epidermal growth factor system in cancerPhase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomasPersonalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker SelectionKirsten Ras* oncogene: Significance of its discovery in human cancer researchRecent developments in receptor tyrosine kinases targeted anticancer therapyIdentifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancerThe Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled TrialsInsulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant diseaseChloroquine and hydroxychloroquine for cancer therapyConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsMagnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapyThe epidermal growth factor receptor variant III (EGFRvIII): where wild things are alteredAcquired resistance to EGFR-targeted therapies in colorectal cancerTumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RASUnderstanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motionOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerPAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signalingLapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumorsStimulus design for model selection and validation in cell signaling1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapyVersican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapyFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentExpression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer CellsQuantitative analysis of ligand-EGFR interactions: a platform for screening targeting moleculesSilencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung AdenocarcinomaAmphiregulin is a novel growth factor involved in normal bone development and in the cellular response to parathyroid hormone stimulationInhibition of cell proliferation by an anti-EGFR aptamerAn active form of Vav1 induces migration of mammary epithelial cells by stimulating secretion of an epidermal growth factor receptor ligandOpen-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative meNovel candidate genes may be possible predisposing factors revealed by whole exome sequencing in familial esophageal squamous cell carcinoma.
P2860
Q24294200-8BA5B053-FF52-49E9-B392-D420A4B989CBQ24538330-9A2A4BC9-B6A9-4EC3-9684-1B8DAE7E57E3Q24648133-173DE141-FB06-4D46-957E-BE60213CFF0BQ24650438-BA523F3B-5C3F-4542-8F22-BCC96482EEFAQ24651229-8533F8D2-0BCC-44B3-BD1A-04C21CB85BF4Q24678674-F133AEF4-D097-460E-B8E6-BC0496E53FAEQ24683709-1C88957D-B20E-47CA-94BB-B2FF6049133EQ24795051-F42F878E-F707-46D8-B1BC-1BAC2980D2D4Q24801944-73D2A867-229F-4375-BB0E-E112ADFB6134Q24813451-2A4AB879-F60B-4972-90FD-4534415A516CQ26738860-925B8AF9-DBE9-4848-ADC3-F3020E4B7740Q26751212-D1AF007E-2C29-4D8D-A247-EAD70B322C7AQ26751331-75C9266A-CBFE-4417-92E2-7FDE154AAA78Q26781810-B6AE8539-77B0-4DA0-9C80-B620FBBB2B2CQ26796549-2FAC4D9B-1404-49BE-8308-E193FD2337A5Q26800001-E6C016B0-EB84-4A42-9886-103ED6A0566FQ26827797-947ED898-FA0F-4C9A-801B-3B724D2245EBQ26830569-422F29C2-F379-4166-A071-0BDD59C90FC1Q27004205-06A0E6B7-1CE5-4B21-839E-74EF866CD3D4Q27015045-203BD6A1-EFD9-4D7F-BC77-C2BAE1A96CFDQ27022741-B53A6354-BB8E-4E9A-9A37-79F9B53926FAQ27645826-79B8FD1D-9013-4C2B-A503-53D60898CA00Q27691330-9E72FE16-E4A3-4EAC-A606-1DE5763EC018Q27853131-3CA3EDAA-25F2-4A1B-9713-C8D44B7AAFC0Q28066285-874CF6C3-DF9D-4C53-812A-818EF57D8CF5Q28077545-97AC3450-6CAC-4644-8B0E-529DFC33E785Q28253621-946686E5-726F-4992-A72C-97193457B96EQ28292264-624C337C-5F07-4DD7-83F3-AF6F15744D21Q28472617-9E0453FB-AC55-4EF4-933B-EB5A07C8AA43Q28476652-D9C64B3A-3CF8-45D8-8C94-BB284393651AQ28477876-5F5EB98F-E684-4D1A-A3A3-841D223CF0C5Q28533949-C5562F88-6F75-489A-A033-A5B36BC0DE8AQ28534094-DAAF8D47-68E5-45A9-B7B9-70384C12DD01Q28543739-3635462E-D1AE-4275-9B23-BDCCB49148C2Q28547292-47885751-283C-487A-95CC-D8AA4B7D4EE4Q28569374-B7094962-16D1-4D62-BFB1-2E46D10BD38EQ28743866-F8EF621B-256E-4355-9B84-27C3B00DB6B0Q30159794-D4509E10-AC70-4EDA-97E4-55CDB1DDE7ACQ30376023-C4B6EB9C-3653-49EB-91BD-72222806FF6DQ30401533-8DD1D246-F6C3-4063-BB8C-92AA62A37908
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The EGF receptor family as targets for cancer therapy.
@ast
The EGF receptor family as targets for cancer therapy.
@en
The EGF receptor family as targets for cancer therapy.
@nl
type
label
The EGF receptor family as targets for cancer therapy.
@ast
The EGF receptor family as targets for cancer therapy.
@en
The EGF receptor family as targets for cancer therapy.
@nl
prefLabel
The EGF receptor family as targets for cancer therapy.
@ast
The EGF receptor family as targets for cancer therapy.
@en
The EGF receptor family as targets for cancer therapy.
@nl
P356
P1433
P1476
The EGF receptor family as targets for cancer therapy.
@en
P2093
J Mendelsohn
P2888
P304
P356
10.1038/SJ.ONC.1204082
P407
P577
2000-12-01T00:00:00Z
P5875
P6179
1011731995